Actively Recruiting
Probiotic Treatment with EXE-346 to Reduce Anal HSIL and Persistent High-Risk HPV Infection in People Living with HIV
Led by University of California, San Francisco · Updated on 2026-10-29
90
Participants Needed
2
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a probiotic treatment called EXE-346 for people living with HIV who have anal high-grade squamous intraepithelial lesions HSIL. The goal is to study whether this approach can help prevent anal cancer by promoting regression of these precancerous lesions. This is a randomized, double-blind, placebo-controlled Phase 2 trial that also assesses the safety of EXE-346. Participants will be randomly assigned to receive either the EXE-346 probiotic or a placebo, both given as powder packets to mix with water and consume twice daily for 12 weeks. The study includes follow-up visits at 24 and 36 weeks after treatment begins. High resolution anoscopy HRA will be performed at weeks 12 and 24 to monitor safety and check for disease progression. If HSIL remains at week 36, participants may receive standard treatment with hyfrecation. During the study, participants will undergo evaluations including biopsies if necessary, safety checks with HRA, and anal swabs to test for HPV types. Researchers will measure the proportion of participants with no disease or disease regression at 36 weeks, as well as HPV clearance and treatment-emergent side effects. The total participation time spans up to 36 weeks, including treatment and follow-up visits, to monitor treatment effects and safety.
CONDITIONS
Brief Title
CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial
Research Team
R
Ross Jamison
J
Jenn Marino
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here